局部复发直肠癌质子束治疗的结局与预后因素
本研究回顾性纳入2008年12月至2019年12月在本院接受质子束治疗的23例局部复发直肠癌患者,中位随访37.4个月,3年和5年总生存率分别为72.1%和44.6%,局部控制率分别为55.0%和47.2%。质子束治疗前18F-FDG-PET/CT最大标准化摄取值(截断值10)在总生存、无进展生存和局部控制上均有显著差异,质子束治疗后达到完全缓解或完全代谢缓解者局部控制显著更优。
要点
- 质子束治疗前18F-FDG-PET/CT最大标准化摄取值(截断值10)与总生存(P=.03)、无进展生存(P=.027)和局部控制(P=.012)显著相关。
- 质子束治疗后达到完全缓解或完全代谢缓解者局部控制显著优于未达到者(HR 4.49,95%CI 1.14-17.63,P=.021)。
- 23例中12例(52%)在质子束治疗后出现进一步局部复发,3例记录到4级晚期胃肠道毒性反应。
核心结论
- 结果表明质子束治疗可能成为局部复发直肠癌的良好治疗选择。
- 质子束治疗前后的18F-FDG-PET/CT可能有助于评估肿瘤反应和预测结局。
研究设计与样本
- 本研究为在本院开展的回顾性研究,纳入2008年12月至2019年12月接受质子束治疗的局部复发直肠癌患者23例,中位随访37.4个月。
- 采用质子束治疗后首次影像学检查进行疗效分层,用Kaplan-Meier法估计总生存、无进展生存和局部控制,用Cox比例风险模型验证各结局的预后因素。
主要发现
- 23例中完全缓解或完全代谢缓解11例,部分缓解或部分代谢缓解8例,疾病稳定或代谢稳定2例,疾病进展或代谢进展2例。
- 3年和5年总生存率分别为72.1%和44.6%,无进展生存率均为37.9%,局部控制率分别为55.0%和47.2%,中位生存时间54.4个月。
- 质子束治疗前18F-FDG-PET/CT最大标准化摄取值(截断值10)在总生存(P=.03)、无进展生存(P=.027)和局部控制(P=.012)上显示出显著差异。
- 质子束治疗后达到完全缓解或完全代谢缓解者局部控制显著优于未达到者(HR 4.49,95%CI 1.14-17.63,P=.021)。
- 年龄≥65岁的患者局部控制率和无进展生存率显著更高;质子束治疗前有疼痛和肿瘤≥30 mm的患者无进展生存率也显著更低。
关键数值与推荐
- 质子束治疗前18F-FDG-PET/CT最大标准化摄取值截断值为10,该值在总生存(P=.03)、无进展生存(P=.027)和局部控制(P=.012)上显示出显著差异。
- 质子束治疗后达到完全缓解或完全代谢缓解者局部控制显著优于未达到者,HR为4.49(95%CI 1.14-17.63,P=.021)。
临床怎么用
- 原文结论指出质子束治疗可能成为局部复发直肠癌的良好治疗选择。
- 原文结论指出质子束治疗前后的18F-FDG-PET/CT可能有助于评估肿瘤反应和预测结局。
局限性
- 23例患者中12例(52%)在质子束治疗后出现进一步局部复发。
- 1例患者发生2级急性放射性皮炎。
- 3例患者记录到4级晚期胃肠道毒性反应,其中2例的再照射与质子束治疗后进一步局部复发相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Our objective was to report the outcome and prognostic factors for patients with locally recurrent rectal cancer (LRRC) treated with proton beam therapy (PBT) at our institution. METHODS AND MATERIALS: The study included PBT-treated patients with LRRC between December 2008 and December 2019. Treatment response was stratified using an initial imaging test after PBT. Overall survival (OS), progression-free survival (PFS), and local control (LC) were estimated using the Kaplan-Meier method. Each outcome's prognostic factors were verified using the Cox proportional hazards model. RESULTS: Twenty-three patients were enrolled (median follow-up, 37.4 months). There were 11 patients with complete response (CR) or complete metabolic response (CMR), 8 with partial response or partial metabolic response, 2 with stable disease or stable metabolic response, and 2 with progressive disease or progressive metabolic disease. Three- and 5-year OS, PFS, and LC were 72.1% and 44.6%, 37.9% and 37.9%, and 55.0% and 47.2%, respectively, with 54.4 months' median survival time. The maximum standardized uptake value of fluorine-18-fluorodeoxyglucose-positron emission tomography-computed tomography (18F-FDG-PET/CT) before PBT (cutoff value, 10) showed significant differences in OS (P = .03), PFS (P = .027), and LC (P = .012). The patients who achieved CR or CMR after PBT had significantly better LC than those with non-CR or non-CMR (hazard ratio, 4.49; 95% confidence interval, 1.14-17.63; P = .021). Older patients (aged ≥65 years) had significantly higher LC and PFS rates. Patients with pain before PBT and larger tumors (≥30 mm) also had significantly lower PFS. Of 23 patients, 12 (52%) experienced further local recurrence after PBT. One patient developed grade 2 acute radiation dermatitis. Regarding late toxicity, grade 4 late gastrointestinal toxic effects were recorded in 3 patients, in 2 of whom reirradiation was associated with further local recurrence after PBT. CONCLUSIONS: The results showed that PBT may have potential to be a good treatment option for LRRC. 18F-FDG-PET/CT before and after PBT may be useful for assessing tumor response and predicting outcomes.
引用
- Takagawa Y, Suzuki M, Yamaguchi H, et al. Outcomes and Prognostic Factors for Locally Recurrent Rectal Cancer Treated With Proton Beam Therapy. Adv Radiat Oncol. 2023. PMID: 36896217. doi:10.1016/j.adro.2023.101192
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。